EU - European customs have stopped millions of illegal medicines

The European Commission recently announced that the customs authorities of the 27 Member States have concentrated efforts over a two-month period under the coordinated "MEDI-FAKE" action, to stop millions of illegal medicines from entering the European Union. On the basis of a risk profile disseminated by the Commission, more than 34 million fake antibiotics, anti-cancer, anti-malaria and anti-cholesterol medicines, as well as painkillers, were successfully seized.
In addition to the intrinsic value for the effectiveness of customs controls, the coordination and co-operation between authorities and the legitimate expectations from legal business, the action is fundamental for protecting European citizens from security and safety threats.
The MEDI-FAKE action also highlighted areas of improvement for future actions in the fight against imports of illegal, dangerous or counterfeit goods, such as increasing cooperation with the interested industries

UE - The Board of Appeal has adopted a decision related to embryonic stem cell patents

The Board of Appeal of the European Patent Office recently adopted a ruling related to the so-called WARF/Thomson stem cell application.
This patent application describes a method to obtain embryonic stem cell cultures from primates, including humans, and was filed by the Wisconsin Alumni Research Foundation in 1995.
The Board of Appela has decided that under the European Patent Convention it is not possible to grant a patent for an invention that requires the use and destruction of human embryos.

The Board stressed, however, that its decision does not concern the general question of human stem cell patentability.

EU - The European Commission publishes a report on the Pharmaceutical Sector Inquiry

The European Commission recently published the preliminary findings of the Pharmaceutical Sector Inquiry launched by the Commission at the beginning of the year. The findings examine the input provided by the pharmaceutical sector under EC competition rules and discuss issues with the use and efficiency of the patent system for the pharmaceutical market, among other topics.
Indeed, the report finds no flaws in the way the patent system works in Europe, although it acknowledges the setback caused by the absence of a Community patent and a centralised European patent judiciary. Moreover, the report examines the patent strategies of the originator companies who first patent and commercialise a pharmaceutical product and possible market barriers created for the generic companies that place generic versions of pharmaceutical products on the market.